Last updated: 2026-09-16 09:46:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Anteris Technologies Global Corp. (AVR) operates in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES sector and is listed on NASDAQ. The stock is currently priced at $8,58, with a market capitalisation of $849,84M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,30 to $11,06. This page covers its latest market performance, valuation, price trends and company information.
$849,84M | |
$8,38 | |
$42,50 | |
$0,09 | |
$8,34 | |
100,00 | |
1,03M | |
-- | |
$11,06 | |
$3,30 | |
-- | |
-- |
Anteris Technologies Global Corp. (AVR) is trading at $8,58 in pre-market trading as of 2026-09-16 09:19:00, up 2,82% ($0,23) from the previous close of $8,34
Pre-market trading shows how investors are pricing AVR before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Anteris Technologies Global Corp. (AVR) moved from $9,04 to $8,58, representing a decline of 5,14% ($0,46).
The stock traded between $8,10 and $9,10 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 593,38 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 68,0%
AVR is currently trading at $8,58, placing it 68,0% of the way from its 52-week low of $3,30 to its 52-week high of $11,06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
| Industry | ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES |
| Employees | 174 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Anteris Technologies Global Corp. (AVR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.